Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events.

Chris A Rogers,Lauren J Scott,Barnaby C Reeves,Susan Downes,Andrew J Lotery,Andrew D Dick,Usha Chakravarthy

Ophthalmology Retina（2018）

引用 22|浏览9

暂无评分

摘要

The decrease in sVEGF is greater with bevacizumab than with ranibizumab, but this difference is eliminated when treatment is withheld for 3 months. Higher sVEGF increased the hazard of an ATE and bevacizumab increases the hazard of an IME compared with ranibizumab.

查看译文

关键词

ATE,CI,DVT,GMR,HR,IME,nAMD,pVEGF,RPE,SSAE,sVEGF,VEGF

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要